Medical Devices - MRI-Compatible Equipment & Infusion Therapy Systems
Strategic Profile
The company highlighted its 17 consecutive quarters of record revenue and cited sustained financial health and strong stock performance as drivers of the recognition. The device maintains Iradimed's unique position as the world's only provider of non-magnetic MRI infusion pumps since 2005. This replacement strategy is a key factor in IRADIMED's projection of breaking through the $100 million revenue run rate in 2026. Domestic pump device revenue is expected to grow from an estimated $28 million in 2025 to nearly $50 million in 2026, driven by these upgrades.
Cyborg Score Rationale
IRADIMED (NASDAQ: IRMD) reported record Q3 2025 revenue of $21.2M (+16% YoY) and record GAAP diluted EPS of $0.43 (non-GAAP diluted EPS $0.47, +9% YoY). IRADIMED CORPORATION (NASDAQ: IRMD) was named to TIME's America's Growth Leaders for 2026, placing 79th among the top 501 U.S. public companies selected by TIME and Statista. Strong operational momentum, consistent revenue growth, and innovation in a specialized medical device niche position the company well for continued expansion.
Top Insights
Limited commercial shipments of the next‑gen 3870 pump are expected in Dec 2025 with full U.S. rollout in Q1 2026.
In the U.S. alone, there are over 6,200 MRI IV pump channels (3860 models) that are 5 years or older and are candidates for replacement. The company aims to add approximately 1,000 replacement channels annually in 2026, increasing this number to over 2,000 and growing in subsequent years.
iRadimed announced a special cash dividend of $0.50 per share, payable on December 30, 2025 to stockholders of record at the close of business on December 17, 2025. The Board said the dividend follows strong financial results, including 17 consecutive quarters of record revenue and a cash and cash equivalents balance of $56.5 million at the end of Q3 2025.
IRADIMED (NASDAQ: IRMD) reported record Q3 2025 revenue of $21.2M (+16% YoY) and record GAAP diluted EPS of $0.43. The company raised full-year 2025 guidance to $82.5M–$83.5M revenue and GAAP EPS to $1.68–$1.72.
Named Competitors
Traditional IV Infusion Pumps — Non-MRI-compatible infusion pump systems
Patient Monitoring Systems — MRI-compatible monitoring alternatives (limited infusion capability)
Recent Developments
(February 2026) Insider director share sale activity; Q1 2026 earnings guidance issued at $0.44-0.48 EPS
(November 2025) Named to TIME's America's Growth Leaders for 2026 (79th place); announced special $0.50/share dividend
(November 2025) Reported record Q3 2025 revenue of $21.2M (+16% YoY); raised full-year 2025 guidance to $82.5M-$83.5M
(October 2025) FDA 510(k) clearance received for next-generation MRidium 3870 IV Infusion Pump System
Open the full interactive IRadimed Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.